Business Context and Reporting Period
This Form 6-K filing by SAGTEC GLOBAL Ltd covers the month of August 2026. The report addresses a regulatory notification received from The Nasdaq Capital Market regarding the listing status of the Company's Class A Ordinary Shares (trading symbol: "SAGT").
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and listing compliance matters.
Material Changes
On August 18, 2026, the Company received notification from Nasdaq that its Class A Ordinary Shares closed below $1.00 for 30 consecutive business days, failing to meet Nasdaq Listing Rule 5550(a)(2). This deficiency does not result in immediate delisting, and trading continues uninterrupted.
Guidance, Outlook, and Risks
- Compliance Period: The Company has 180 calendar days, until February 16, 2027, to regain compliance. Compliance is achieved if the closing bid price is at least $1.00 for 10 consecutive business days.
- Contingency Plan: If compliance is not met by the deadline, the Company may be eligible for an additional 180-day grace period, provided it meets other listing standards (excluding bid price) and intends to cure the deficiency, potentially via a reverse stock split.
- Reverse Stock Split: If implemented, a reverse stock split must be completed no later than 10 business days prior to February 16, 2027.
- Delisting Risk: Failure to cure the deficiency or qualify for an extension may lead to delisting. The Company retains the right to appeal a delisting determination to a hearings panel.
Investor Verification Checklist
- Verify the current closing bid price of SAGT shares to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split before the February 16, 2027 deadline.
- Review the Company's market value of publicly held shares to ensure eligibility for a potential second compliance period.
- Check for any subsequent correspondence from Nasdaq regarding the status of the deficiency.